After Morgan Stanley and H.C. Wainwright gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Sarepta Therapeutics today and set a price target of $213. The company’s shares closed on Friday at $151.95.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 25.5% and a 50.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $202.08, which is a 33.0% upside from current levels. In a report issued on June 17, H.C. Wainwright also maintained a Buy rating on the stock with a $267 price target.
See today’s analyst top recommended stocks >>
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $76.64 million. In comparison, last year the company had a GAAP net loss of $109 million.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 10,000 shares for a total of $1,200,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.